Download presentation
Presentation is loading. Please wait.
Published byYanti Kusnadi Modified over 5 years ago
1
Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization Birgitta Sigvant, MD, PhD, Björn Kragsterman, MD, PhD, Mårten Falkenberg, MD, PhD, Pål Hasvold, MSc Pharm, Saga Johansson, MD, PhD, Marcus Thuresson, PhD, Joakim Nordanstig, MD, PhD Journal of Vascular Surgery Volume 64, Issue 4, Pages e3 (October 2016) DOI: /j.jvs Copyright © 2016 The Authors Terms and Conditions
2
Fig 1 Kaplan-Meier estimates of the risk of the primary composite end point (myocardial infarction, ischemic stroke, or cardiovascular [CV] death), all-cause mortality, and myocardial infarction and ischemic stroke after revascularization, separated by peripheral artery disease (PAD) stage. CI, Confidence interval; CVD, cardiovascular disease; HR, hazard ratio. Journal of Vascular Surgery , e3DOI: ( /j.jvs ) Copyright © 2016 The Authors Terms and Conditions
3
Fig 2 Persistence to preventive drug treatment for intermittent claudication (IC) and critical limb ischemia (CLI). ACEi, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker. Journal of Vascular Surgery , e3DOI: ( /j.jvs ) Copyright © 2016 The Authors Terms and Conditions
4
Fig 3 Time trends for best medical treatment (BMT; antiplatelet or anticoagulant therapy and statin treatment) 1 month after revascularization of claudication and critical lower limb ischemia patients. Journal of Vascular Surgery , e3DOI: ( /j.jvs ) Copyright © 2016 The Authors Terms and Conditions
5
Supplementary Fig (online only)
Age distribution for claudication and critical lower limb ischemia patients at admission for revascularization. Journal of Vascular Surgery , e3DOI: ( /j.jvs ) Copyright © 2016 The Authors Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.